Interim Analysis Expected End of 2Q 2025BETHESDA, MD, Mar 14, 2025 - (ACN Newswire) - Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

Airoha Technology (Airoha) secured a NT$1.4 billion (approx. US$ 42.59 million) grant from Taiwan's Ministry of Economic ...

Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...

AI made a substantial contribution to Foxconn's (Hon Hai Technology Group) sales growth in 2024. Looking ahead, Chairman ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Xilio expects to report updated data from the Phase 2 clinical trial in the middle of 2025, including additional response ...

Recently, a team from the University of Science and Technology of China (USTC), led by Haiding Sun, has demonstrated a ...

Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...